E. Pulczynski

发表

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

F. Cavalli, J. Panse, M. Falautano, 2022, Leukemia.

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

F. Cavalli, F. Angrilli, V. Torri, 2017, The Lancet. Haematology.

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

F. Cavalli, V. Torri, J. Panse, 2016, The Lancet. Haematology.

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

J. Armitage, E. Thiel, F. Cavalli, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.

J. Blay, B. O'neill, K. Hoang-Xuan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by The Nordic Lymphoma Group

M. Eriksson, B. Østenstad, Ø. Fluge, 2015, Haematologica.

Addition of Thiotepa and Rituximab to Antimetabolites Significantly Improves Outcome in Primary CNS Lymphoma: First Randomization of the IELSG32 Trial.

F. Cavalli, R. Soffietti, M. Reni, 2015, Clinical advances in hematology & oncology : H&O.

Improved outcome with addition of thiotepa and rituximab to methotrexate and cytarabine in primary cns lymphoma: Results of the first randomization of the IELSG-32 trial

A. Ferrer, F. Cavalli, R. Soffietti, 2015 .

The Danish National Chronic Lymphocytic Leukemia Registry

P. de Nully Brown, C. Geisler, C. Niemann, 2016, Clinical epidemiology.

RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Jeffrey A Jones, F. Bosch, P. Feugier, 2015 .

Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review

J. Rubenstein, E. Pulczynski, Mazie Tsang, 2021, Annals of lymphoma.

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

G. Lenz, J. Panse, T. Calimeri, 2022, Blood.